Published in Women's Health Weekly, April 8th, 2004
"Our objective was to evaluate the activity and safety of the combination of cisplatin, epirubicin and vinorelbine (CEV) in advanced breast cancer patients. Patients with advanced breast cancer, locally advanced or metastatic, received epirubicin 75 mg/m2 and cisplatin 50 mg/m2 on day 1, and vinorelbine 25 mg/m2 on day 5. Cycles were repeated every 3 weeks," investigators in Italy report.
"A total of 35 patients were treated. Thirty-one patients were evaluated for response. One hundred...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly